Authorized purpose: Contour ProtégéAI+ processes CT and MR DICOM images and generates contours for quantitative analysis, adaptive therapy, image registration, transfer to radiotherapy planning, and archiving subject to qualified review and editing.
Radiological images; modality varies or is not specified in FDA list · Multi-region
Key limitation
Keep in mind: Anatomy, modality, structure set, registration, treatment site, software version, and required independent checks are release-specific. Contour ProtégéAI+ processes CT and MR DICOM images and generates contours for quantitative analysis, adaptive therapy, image registration, transfer to radiotherapy planning, and archiving subject to qualified review and editing.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Contour ProtégéAI+ processes CT and MR DICOM images and generates contours for quantitative analysis, adaptive therapy, image registration, transfer to radiotherapy planning, and archiving subject to qualified review and editing.
Which images or clinical context are in scope?Modality: Radiological images; modality varies or is not specified in FDA list Anatomy or clinical context: Multi-region Input: Supported CT or MR DICOM studies, contours, treatment-planning metadata, and release-specific workflow inputs.
Who uses it?Intended users: Qualified radiation oncologists, dosimetrists, physicists, therapists, and trained imaging professionals.
What does the software produce?Output: Contours, registrations, measurements, processed images, or planning-workflow objects for qualified review and approval.
What is its most important limitation?Key limitation: Anatomy, modality, structure set, registration, treatment site, software version, and required independent checks are release-specific. Contour ProtégéAI+ processes CT and MR DICOM images and generates contours for quantitative analysis, adaptive therapy, image registration, transfer to radiotherapy planning, and archiving subject to qualified review and editing.
Clinical takeaway. Clinical role: Contour ProtégéAI+ processes CT and MR DICOM images and generates contours for quantitative analysis, adaptive therapy, image registration, transfer to radiotherapy planning, and archiving subject to qualified review and editing.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports verification and validation in which the subject device was evaluated on test subjects from a pool of 189 images gathered from 7 institutions, using non-inferiority testing against atlases from the MIM Maestro reference device, Dice and MDA versus original ground-truth contours, and user beta testing of time savings. Each individual feature met the acceptance criteria; the CT Male Pelvis model showed a performance reduction on female patients. Results are as reported in the FDA submission, not independent validation.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Contour ProtégéAI+ processes CT and MR DICOM images and generates contours for quantitative analysis, adaptive therapy, image registration, transfer to radiotherapy planning, and archiving subject to qualified review and editing.
Anatomy, modality, structure set, registration, treatment site, software version, and required independent checks are release-specific. Contour ProtégéAI+ processes CT and MR DICOM images and generates contours for quantitative analysis, adaptive therapy, image registration, transfer to radiotherapy planning, and archiving subject to qualified review and editing.
The exact FDA document reports verification and validation in which the subject device was evaluated on test subjects from a pool of 189 images gathered from 7 institutions, using non-inferiority testing against atlases from the MIM Maestro reference device, Dice and MDA versus original ground-truth contours, and user beta testing of time savings. Each individual feature met the acceptance criteria; the CT Male Pelvis model showed a performance reduction on female patients. Results are as reported in the FDA submission, not independent validation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Non-inferiority testing was used to compare the Contour ProtégéAI+ subject device to Atlases created from the MIM Maestro (K071964) reference device." … "The Contour ProtégéAI+ subject device was evaluated on the test subjects from a pool of 189 images gathered from 7 institutions.". Read from the exact FDA decision document on 2026-11-14.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact FDA document reports verification and validation in which the subject device was evaluated on test subjects from a pool of 189 images gathered from 7 institutions, using non-inferiority testing against atlases from the MIM Maestro reference device, Dice and MDA versus original ground-truth contours, and user beta testing of time savings. Each individual feature met the acceptance criteria; the CT Male Pelvis model showed a performance reduction on female patients. Results are as reported in the FDA submission, not independent validation.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "Non-inferiority testing was used to compare the Contour ProtégéAI+ subject device to Atlases created from the MIM Maestro (K071964) reference device." … "The Contour ProtégéAI+ subject device was evaluated on the test subjects from a pool of 189 images gathered from 7 institutions.". Read from the exact FDA decision document on 2026-11-14.
No exact submission and version-linked sensitivity endpoint is published in this dossier; do not substitute a product-family or candidate-study value.
Reported specificity
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-04
No exact submission and version-linked specificity endpoint is published in this dossier; do not substitute a product-family or candidate-study value.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
FDA submission-specific verification and validation evidence for K253270
DesignRegulatory verification, validation, and labeling evidence reviewed for exact FDA submission K253270.
PopulationThe labeled population and test materials for exact submission K253270; a general clinical study population is not established here.
Scopeexact submission
Tested versionContour ProtégéAI+ (K253270)
IndependenceSponsor or vendor study
K253270
FDA regulatory evidence is submission-specific but is not independent clinical performance evidence.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-04
No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.
Pricing & contractsPublic price, contract terms, and reimbursement
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Supported CT or MR DICOM studies, contours, treatment-planning metadata, and release-specific workflow inputs.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. Exact submission evidence and the current vendor family material do not establish the exact site's DICOM, worklist, PACS/RIS, identity, routing, display, or fallback behavior.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Field checked 2026-09-04 ·
AI processing
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. Exact deployment topology, hosting, network boundaries, update mechanism, and local operational requirements are not established for this submission.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-09-04 ·
Returned objects
Source context, not route validation: Contours, registrations, measurements, processed images, or planning-workflow objects for qualified review and approval.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Contours, registrations, measurements, processed images, or planning-workflow objects for qualified review and approval.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
MIM Software's security page states SOC 2 Type 2 status, penetration testing and continuous vulnerability scanning of released products, coordinated vulnerability disclosure and a public security advisories page. Vendor-wide.
Vendor-wide
Checked 2026-10-25
Vendor statement, not an attestation; exact-release scope is not established.
Current vendor material is product-family context for K253270 only; exact release, enabled options, deployment, and local interoperability require confirmation.
product family · checked 2026-09-04
Vendor material is not exact-release evidence unless that linkage is separately proven.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-19Last searched
28Fields reviewed
14Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, vendor documentation, fda decision summary, vendor product page, implementation documentation, reimbursement policy, peer reviewed literature, clinical trial registry, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission
No public exact-release price, license fee, subscription, contract, or implementation cost was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not applicable - checked 2026-09-04 - Not applicable
CMS index context was checked, but no product-specific coverage or reimbursement determination is inferred.
Deployment: Not publicly available - checked 2026-09-04 - Exact FDA submission
Exact deployment topology, hosting, network boundaries, update mechanism, and local operational requirements are not established for this submission.
Integration: Not publicly available - checked 2026-09-04 - Exact FDA submission
Exact submission evidence and the current vendor family material do not establish the exact site's DICOM, worklist, PACS/RIS, identity, routing, display, or fallback behavior.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-10-27 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-10-27 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: AiORTA - Plan v2.0 is image-processing and analysis software for the labeled radiotherapy-planning workflow; exact modalities, structures, inputs, outputs, and user-review requirements remain submission-specific.
Modality
Radiological images; modality varies or is not specified in FDA list
Authorized purpose: Synapse PACS version 7.5 provides primary processing and presentation of DICOM and supported non-DICOM images with measurement, segmentation, fusion, volume rendering, reporting, integrated 3D, two-point VOI, and AI-assisted bone removal.
Modality
Radiological images; modality varies or is not specified in FDA list
Authorized purpose: CT and MR 3D segmentation, measurements and interactive models for adult preoperative and intraoperative surgical planning; not primary diagnosis.
Modality
Radiological images; modality varies or is not specified in FDA list
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.